Twenty percent of NRAS mutant-driven melanoma patients had partial response to MEK inhibitor binimetinib in a phase II clinical trial.441 Similarly, targeting ERK kinase, the downstream effector of MEK, failed to show clinical benefits in treating RAS mutant cancer. This evidence concerns the gene MAP2K7 and cancer.